What is cjc 1295

Overview

CJC 1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), a natural hormone produced in the hypothalamus that signals the pituitary gland to release growth hormone. The compound was developed through modifications of naturally occurring GHRH to create a more stable and longer-acting version. CJC 1295 is primarily used in research and clinical investigations related to growth hormone physiology and potential therapeutic applications.

Mechanism of Action

CJC 1295 works by binding to GHRH receptors on cells in the anterior pituitary gland, stimulating the release of growth hormone. Growth hormone plays crucial roles in numerous body functions including muscle growth, fat metabolism, bone density, and cellular regeneration. By increasing growth hormone secretion, CJC 1295 can theoretically enhance these physiological processes. The peptide does not directly increase growth hormone in the bloodstream but rather stimulates the body's natural production mechanism.

Forms and Administration

CJC 1295 exists in two primary formulations. The standard version has a relatively short half-life and requires more frequent dosing. The modified version, CJC 1295 DAC (where DAC stands for Drug Affinity Complex), includes an albumin-binding domain that extends the half-life significantly, allowing for less frequent administration. Both forms are typically administered via subcutaneous or intramuscular injection. Research protocols typically involve doses ranging from 1-2 micrograms per kilogram of body weight.

Research Applications and Status

CJC 1295 has been investigated for potential applications in treating growth hormone deficiency, age-related conditions, and metabolic disorders. Ongoing research explores its effects on body composition, muscle development, and recovery from injury or illness. The regulatory status of CJC 1295 varies by jurisdiction. In many countries, it is classified as a research chemical and is not approved for human therapeutic use outside clinical trials. Interest in the compound remains active within medical research communities investigating growth hormone physiology and potential therapeutic applications for growth hormone deficiency disorders.